Pharmaceuticals

Global Biologic & Biosimilar RA Drugs Market Overview: Trends Shaping Growth to 2029

November 7, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Expected Total Market Size Of The Biologic & Biosimilar RA Drugs Industry By The Forecast Year 2029?

The market size for biologic & biosimilar ra drugs has experienced consistent expansion in recent years. It is forecast to rise from $13.99 billion in 2024 to $14.57 billion in 2025, achieving a compound annual growth rate (CAGR) of 4.1%. This historical growth can be attributed to elements such as market adoption rates, clinical trial outcomes, changes in market share, long-term patient outcomes, and various pricing strategies.

The market for biologic & biosimilar ra drugs is projected to experience substantial expansion in the coming years. This market is anticipated to reach $19.08 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.0%. This anticipated growth during the forecast period is attributable to factors such as accelerated biologic drug development, intense market competition, evolving healthcare policies, changing patient preferences, and ongoing clinical research & development. Key trends identified for this period encompass a surge in biosimilar market rivalry, the adoption of personalized medicine and precision therapy, innovations in drug delivery systems, an emphasis on safety and efficacy, and a shift towards patient-centric healthcare.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9255&type=smp

Which Drivers Are Supporting Growth Of The Biologic & Biosimilar RA Drugs Market?

The biologics and biosimilar RA drugs market is experiencing growth driven by the expanding elderly demographic and a greater occurrence of rheumatoid arthritis. Individuals aged 60 years or more are defined as the older population. Rheumatoid arthritis, an autoimmune condition, involves a person’s immune system attacking healthy cells, primarily impacting their joints. This condition predominantly affects seniors, as the immune system naturally weakens with advancing age. Compared to traditional medications, biologics and biosimilar RA drugs offer significant benefits in treating rheumatoid arthritis. For example, the World Health Organization (WHO), a Switzerland-based specialized health agency of the United Nations, reported approximately 1 billion individuals aged 60 and older globally in 2020, with projections indicating this demographic will expand to 1.4 billion by 2030 and 2.1 billion by 2050. Additionally, data from the Centers for Disease Control and Prevention, a US-based governmental public health agency, suggests that the count of adults with arthritis in the USA is anticipated to climb to 78.4 million by 2040, with 34.6 million potentially experiencing limitations in activities due to arthritis. Consequently, the growing senior population, coupled with a rise in rheumatoid arthritis instances, is propelling the biologics and biosimilar RA drugs market ahead.

Which Key Segments Fueling The Biologic & Biosimilar RA Drugs Market?

The biologic & biosimilar ra drugs market covered in this report is segmented –

1) By Source: Microbial, Mammalian, Other Sources

2) By Disease: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases

3) By Manufacturing: Outsourced, In-House

4) By Mode Of Purchase: Prescription Drugs, Over-The-Counter (OTC) Drugs

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Microbial: Bacterial Sources, Fungal Sources, Yeast Sources

2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cell Lines

3) By Other Sources: Plant-Based Sources, Insect-Based Sources, Synthetic Biology Approaches

What Are The Latest Industry Trends Transforming The Biologic & Biosimilar RA Drugs Market?

A significant trend gaining traction in the biologic & biosimilar RA drugs market involves novel innovations. Leading companies within the biologic & biosimilar RA drugs market are concentrating on creating biosimilar treatments, like Dual Concentration Biosimilar Options, to offer more economical choices. For example, in July 2023, Organon, a US-based healthcare firm, along with Samsung Bioepis, a South Korea-based biopharmaceutical enterprise, introduced HADLIMA, an adalimumab biosimilar of Humira, into the US market. Offered in both high and low concentrations, HADLIMA seeks to improve accessibility and lower costs for individuals suffering from autoimmune conditions. This biosimilar is retailed at an 85% discount compared to Humira, thus broadening patient availability. HADLIMA features an autoinjector, endorsed by the Arthritis Foundation, alongside a patient support initiative named HADLIMA For You, which provides educational materials and co-pay assistance. Its indications cover multiple conditions, such as rheumatoid arthritis and Crohn’s disease. HADLIMA comes in both a citrate-free high concentration (100 mg/mL) and a citrate-containing low concentration (50 mg/mL), ensuring uninterrupted care for patients.

Which Leading Companies Dominate The Biologic & Biosimilar RA Drugs Market Share?

Major companies operating in the biologic & biosimilar RA drugs market include Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC., Teva Pharmaceutical Industries Ltd., Fresenius Se & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy’s Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/biologic-and-biosimilar-ra-drugs-global-market-report

Which Region Currently Holds The Largest Share Of The Biologic & Biosimilar RA Drugs Market?

North America was the largest region in the biologic & biosimilar RA drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Biologic & Biosimilar RA Drugs Market Report:

https://www.thebusinessresearchcompany.com/customise?id=9255&type=smp

Browse Through More Reports Similar to the Global Biologic & Biosimilar RA Drugs Market 2025, By The Business Research Company

Cardiovascular Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report

Dermatology Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Gastrointestinal Drug Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795